Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Multitarget Therapeutic Strategies for Alzheimer’s Disease: Review on Emerging Target Combinations
Samuele Maramai, Mohamed Benchekroun, Moustafa T. Gabr, et al.
BioMed Research International (2020) Vol. 2020, pp. 1-27
Open Access | Times Cited: 88

Showing 26-50 of 88 citing articles:

Potential of Tryptamine Derivatives as Multi-Target Directed Ligands for Alzheimer’s Disease: AChE, MAO-B, and COX-2 as Molecular Targets
Saira Asghar, Nousheen Mushtaq, Ahsaan Ahmed, et al.
Molecules (2024) Vol. 29, Iss. 2, pp. 490-490
Open Access | Times Cited: 3
Design, synthesis, and biological evaluation of novel (4-(1,2,4-oxadiazol-5-yl)phenyl)-2-aminoacetamide derivatives as multifunctional agents for the treatment of Alzheimer's disease
Tongtong Liu, Shiming Chen, Jiyu Du, et al.
European Journal of Medicinal Chemistry (2021) Vol. 227, pp. 113973-113973
Closed Access | Times Cited: 26
New Pyrimidine and Pyridine Derivatives as Multitarget Cholinesterase Inhibitors: Design, Synthesis, and In Vitro and In Cellulo Evaluation
Martina Bortolami, Fabiana Pandolfi, Valeria Tudino, et al.
ACS Chemical Neuroscience (2021) Vol. 12, Iss. 21, pp. 4090-4112
Open Access | Times Cited: 23
Design, synthesis, characterization and evaluation of 1,3,5-triazine-benzimidazole hybrids as multifunctional acetylcholinesterases inhibitors
Wenlong Wu, Ze-Yu Wen, Jing‐Jing Qian, et al.
Journal of Molecular Structure (2022) Vol. 1257, pp. 132498-132498
Closed Access | Times Cited: 17
Exploration of Neuroprotective Properties of a Naturally Inspired Multifunctional Molecule (F24) against Oxidative Stress and Amyloid β Induced Neurotoxicity in Alzheimer’s Disease Models
Yash Pal Singh, Navneet Kumar, Khushbu Priya, et al.
ACS Chemical Neuroscience (2021) Vol. 13, Iss. 1, pp. 27-42
Closed Access | Times Cited: 21
Multitargeted Virtual Screening and Molecular Simulation of Natural Product-like Compounds against GSK3β, NMDA-Receptor, and BACE-1 for the Management of Alzheimer’s Disease
Danish Iqbal, Md Tabish Rehman, Mohamed F. Alajmi, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 4, pp. 622-622
Open Access | Times Cited: 8
A Multitarget Approach against Neuroinflammation: Alkyl Substituted Coumarins as Inhibitors of Enzymes Involved in Neurodegeneration
Emanuela Berrino, Simone Carradori, Fabrizio Carta, et al.
Antioxidants (2023) Vol. 12, Iss. 12, pp. 2044-2044
Open Access | Times Cited: 8
BACE1 inhibitors: A promising therapeutic approach for the management of Alzheimer’s disease
Richa Arya, Smita Jain, Sarvesh Paliwal, et al.
Asian Pacific Journal of Tropical Biomedicine (2024) Vol. 14, Iss. 9, pp. 369-381
Open Access | Times Cited: 2
Jatamansinol from Nardostachys jatamansi (D.Don) DC. Protects Aβ42-Induced Neurotoxicity in Alzheimer's Disease Drosophila Model
Kizhakke P. Anupama, Shilpa Olakkaran, Anet Antony, et al.
NeuroToxicology (2022) Vol. 90, pp. 62-78
Closed Access | Times Cited: 13
Therapeutic approach with commercial supplements for pantothenate kinase-associated neurodegeneration with residual PANK2 expression levels
Mónica Álvarez-Córdoba, Diana Reche-López, Paula Cilleros-Holgado, et al.
Orphanet Journal of Rare Diseases (2022) Vol. 17, Iss. 1
Open Access | Times Cited: 13
Pharmacogenomics of Alzheimer’s Disease: Novel Strategies for Drug Utilization and Development
Ramón Cacabelos, Vinogran Naidoo, Olaia Martínez-Iglesias, et al.
Methods in molecular biology (2022), pp. 275-387
Closed Access | Times Cited: 13
Personalized Management and Treatment of Alzheimer’s Disease
Ramón Cacabelos, Vinogran Naidoo, Olaia Martínez-Iglesias, et al.
Life (2022) Vol. 12, Iss. 3, pp. 460-460
Open Access | Times Cited: 12
Anti‐Alzheimer's Activity of Polyphenolic Stilbene‐Rich Acetone Fraction of the Oil‐Removed Seeds of Passiflora edulis: in Vivo and in Silico Studies
Nadjet Mostefa, Noureddine Djebli, Pham Ngoc Khanh, et al.
Chemistry & Biodiversity (2023) Vol. 20, Iss. 5
Open Access | Times Cited: 7
Piperidine Nucleus as a Promising Scaffold for Alzheimer’s Disease: Current Landscape and Future Perspective
Parul Grover, Suman Rohilla, Monika Bhardwaj, et al.
Current Topics in Medicinal Chemistry (2023) Vol. 23, Iss. 13, pp. 1221-1259
Closed Access | Times Cited: 7
Investigation on Novel E/Z 2-Benzylideneindan-1-One-Based Photoswitches with AChE and MAO-B Dual Inhibitory Activity
Marco Paolino, Modesto de Candia, Rosa Purgatorio, et al.
Molecules (2023) Vol. 28, Iss. 15, pp. 5857-5857
Open Access | Times Cited: 7
PEA-OXA ameliorates allodynia, neuropsychiatric and adipose tissue remodeling induced by social isolation
Carmela Belardo, Nicola Alessio, Martina Pagano, et al.
Neuropharmacology (2022) Vol. 208, pp. 108978-108978
Closed Access | Times Cited: 11
Pharmacophore-Based Screening, Molecular Docking, and Dynamic Simulation of Fungal Metabolites as Inhibitors of Multi-Targets in Neurodegenerative Disorders
Danish Iqbal, Mohammed Alsaweed, Qazi Mohammad Sajid Jamal, et al.
Biomolecules (2023) Vol. 13, Iss. 11, pp. 1613-1613
Open Access | Times Cited: 6
Fluoxetine and sertraline based multitarget inhibitors of cholinesterases and monoamine oxidase-A/B for the treatment of Alzheimer's disease: Synthesis, pharmacology and molecular modeling studies
Muhammad Shahid Nadeem, Jalaluddin Azam Khan, Umer Rashid
International Journal of Biological Macromolecules (2021) Vol. 193, pp. 19-26
Closed Access | Times Cited: 15
Cyanobiphenyls: Novel H3 receptor ligands with cholinesterase and MAO B inhibitory activity as multitarget compounds for potential treatment of Alzheimer’s disease
Justyna Godyń, Paula Zaręba, Dorota Łażewska, et al.
Bioorganic Chemistry (2021) Vol. 114, pp. 105129-105129
Open Access | Times Cited: 14
What is the gold standard model for Alzheimer’s disease drug discovery and development?
Ramón Cacabelos, Iván Carrera, Olaia Martínez-Iglesias, et al.
Expert Opinion on Drug Discovery (2021) Vol. 16, Iss. 12, pp. 1415-1440
Closed Access | Times Cited: 14
First-in-Class Isonipecotamide-Based Thrombin and Cholinesterase Dual Inhibitors with Potential for Alzheimer Disease
Rosa Purgatorio, Nicola Gambacorta, Modesto de Candia, et al.
Molecules (2021) Vol. 26, Iss. 17, pp. 5208-5208
Open Access | Times Cited: 14
Advances in the discovery of heterocyclic-based drugs against Alzheimer’s disease
J. Domingo Sánchez, Andrés R. Alcántara, Juan F. González, et al.
Expert Opinion on Drug Discovery (2023) Vol. 18, Iss. 12, pp. 1413-1428
Closed Access | Times Cited: 5
Recent Advances in Enzyme Inhibition: A Pharmacological Review
Kuldeep Singh, Bharat Bhushan, Nidhi Mittal, et al.
Current Enzyme Inhibition (2023) Vol. 20, Iss. 1, pp. 2-19
Closed Access | Times Cited: 5
Targeting CB2 and TRPV1: Computational Approaches for the Identification of Dual Modulators
Paula Morales, Chanté Muller, Nadine Jagerovic, et al.
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 9
DESIGN, SYNTHESIS, BIOLOGICAL EVALUATION AND MOLECULAR DOCKING OF PYRROLE-BASED COMPOUNDS AS ANTIOXIDANT AND MAO-B INHIBITORY AGENTS
Emilio Mateev
FARMACIA (2022) Vol. 70, Iss. 2, pp. 344-354
Open Access | Times Cited: 9

Scroll to top